ClinicalTrials.gg
CompletedNCT06108219Updated Sep 29, 2026

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

A Phase 2 interventional study of Miricorilant (Cohort A) and Placebo (Cohort A) in Nonalcoholic Steatohepatitis (NASH) and Metabolic Dysfunction-associated Steatohepatitis (MASH), sponsored by Corcept Therapeutics. Completed at 77 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment

Updated Sep 28, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
89th of 460
175 · median 56
Started
2023
with 36 others
Phase 2
192 of 547
15 open now
Registered
497th of 547
by date
Lead sponsor
8 of 547
Corcept Therapeutics

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 89th largest by enrollment of the 460 interventional ones that give a count, is one of 37 that started in 2023, is one of 192 in phase 2, and was the 497th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Read the detailed description

Approximately 75 patients who are eligible for participation in the study will be randomized on Day 1 in a 2:1 ratio to 100 mg miricorilant or placebo twice weekly, for 48 weeks of treatment (Cohort A).

Approximately 90 patients who are eligible for participation in the study will be randomized on Day 1 in a 2:1 ratio to 100 mg miricorilant twice a week for 6 weeks of treatment, followed by a dose escalation to 200 mg miricorilant or placebo twice weekly for an additional 18 weeks which resulting in a total treatment duration of 24 weeks, or to placebo for 24 weeks. (Cohort B).

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)
  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Keywords

  • Nonalcoholic Steatohepatitis (NASH)
  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Metabolic dysfunction-Associated Steatohepatitis (MASH)
  • Metabolic dysfunction-Associated Steatosis Liver Disease (MASLD)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort A: Histological diagnosis of NASH/MASH with NAS ≥ 4 (≥ 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH-CRN fibrosis score of 2 or 3 based on the consensus method of histological assessment. A historical liver within 6 months of Screening with reading confirmed during the Screening period by a consensus panel is acceptable.
  • Cohort B: Have a liver biopsy result that does not meet with the criteria for inclusion in Cohort A and is consistent with one of the following based on the consensus method of histological assessment:

    • NAS ≥ 3 with ≥1 point in each subcomponent of steatosis, inflammation, and ballooning, and a NASH-CRN fibrosis score of F1 or
    • NAS ≥ 2 with ≥1 point in subcomponent of steatosis and ≥ 1 point in subcomponent of ballooning or inflammation and a NASH-CRN fibrosis score of F2 or 3
  • > 17 U/L for women and AST > 20 U/L for men.
  • FibroScan® liver stiffness measurement ≥ 8 kPa and CAP ≥ 280 dB/m.
  • MRI-PDFF with ≥ 8% steatosis
  • Presence of at least 1 of the following metabolic syndromes that increase the risk of NASH/MASH:

    1. Diagnosis of type 2 diabetes OR
    2. Presence of 2 or more components of metabolic syndrome:

    i. Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or treatment for elevated blood glucose ii. Systolic blood pressure ≥ 130mmHg, diastolic blood pressure ≥ 85mmHg, or treatment for hypertension iii. Serum triglycerides ≥ 150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides iv. Serum high-density lipoprotein (HDL) cholesterol \< 40 mg/dL (1 mmol/L) in men and \< 50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL v. Overweight or obese ( [BMI] ≥ 25 kg/m2 [BMI ≥ 23 kg/m2 in Asians]), or increased waist circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) in women (male ≥ 90 cm [35.4 in]; women ≥ 80 cm [31.5 in] in

  • Other inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Have participated in another clinical trial within the last 3 months of Screening where the patient received active treatment for NASH/MASH.
  • Have participated in a clinical trial for any other indication within the last 3 months or 5 half-lives of the treatment, whichever is longer.
  • Are pregnant or lactating women
  • Have a \< 18 kg/m2 or > 45 kg/m2.• Have had liver transplantation or plan to have liver transplantation during the study
  • Have type 1 diabetes or poorly controlled type 2 diabetes.
  • Are pregnant or lactating women
  • Have a BMI \< 18 kg/m2 or > 45 kg/m2
  • Have had successful weight-loss surgery within 2 years prior to Screening or are planning weight-loss surgery during the study.
  • Have a >5% weight change within 3 months prior to Screening.
  • Have significant alcohol consumption of more than 20 g per day for women and 30 g per day for men within 1 year prior to screening or score of ≥8 on AUDIT questionnaire
  • Have any other chronic liver disease
  • History of cirrhosis or evidence of cirrhosis by clinical, imaging, or liver evaluation
  • Have hepatic decompensation
  • Other exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Experimental (Cohort A)

    Patients who meet the entry criteria for study CORT118335-862 (Cohort A) will be enrolled to receive 100 mg of miricorilant, twice a week for 48 weeks.

    Drug: Miricorilant (Cohort A)

  • Placebo comparator
    Placebo (Cohort A)

    Patients who meet the entry criteria for study CORT118335-862 (Cohort A) will be enrolled to receive a matching placebo twice a week for 48 weeks.

    Drug: Placebo (Cohort A)

  • Placebo comparator
    Placebo (Cohort B)

    Patients who meet the entry criteria for study CORT118335-862 (Cohort B) will be enrolled to receive a matching placebo twice a week for 24 weeks.

    Drug: Placebo (Cohort B)

  • Experimental
    Experimental (Cohort B)

    Patients who meet the entry criteria for study CORT118335-862 (Cohort B) will be enrolled to receive 100 mg of miricorilant, twice a week for 6 weeks. Dose will be escalated to 200 mg of miricorilant, twice a week for 18 weeks.

    Drug: Miricorilant (Cohort B)

Interventions

  • Miricorilant 100 mg for oral dosing

    Also known as: CORT118335

  • DrugPlacebo (Cohort A)

    Matching placebo for oral dosing for 48 Weeks

  • Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing

    Also known as: CORT118335

  • DrugPlacebo (Cohort B)

    Matching placebo for oral dosing for 24 Weeks

06

What researchers measure

Primary outcomes

  1. Percent relative change from Baseline in liver-fat content assessed by MRI-PDFF (Cohort A and Cohort B)

    Time frame: Week 24

Secondary outcomes

  1. Percent relative change from Baseline in liver-fat content by MRI-PDFF (Cohort A and B at Week 6 and 24, Cohort A at Week 48)

    Time frame: Week 6 and 24, Week 48

  2. Absolute change from Baseline in liver-fat content by MRI-PDFF (Cohort A and B at Week 6 and 24, Cohort A at Week 48)

    Time frame: Week 6, 24, Week 48

  3. Resolution of steatohepatitis (defined as a ballooning grade of 0 and a lobular inflammation grade of ≤ 1) and no worsening of liver fibrosis at Week 48 assessed by biopsy (Cohort A).

    Time frame: Week 48

  4. Proportion of patients with at least 2 points reduction from Baseline in the NAS (NAFLD activity score) without worsening of liver fibrosis at Week 48 assessed by biopsy, with at least a 1-point reduction in ballooning or inflammation (Cohort A).

    Time frame: Week 48

  5. Improvement in liver fibrosis stage by at least 1-point (NASH CRN fibrosis score) from Baseline and no worsening of steatohepatitis at Week 48 assessed by biopsy (Cohort A).

    Time frame: Week 48

  6. Change in liver stiffness and Controlled Attenuation Parameter (CAP) by FibroScan. (Cohort A and Cohort B at Week 24, Cohort A at Week 48)

    Time frame: Week 24 and 48

  7. Change in absolute body weight (Cohort A and B at Week 24, Cohort A at Week 48)

    Time frame: Week 24 and 48

  8. Change in lipids - total cholesterol, HDL, LDL, VLDL, TG, serum free fatty acids, (Cohort A and Cohort B at Week 24, Cohort A at Week 48)

    Time frame: Week 24 and 48

  9. Change in Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) (Cohort A and Cohort B at Week 6 and 24, Cohort A at Week 48)

    Time frame: Week 6, 24 and 48

  10. Proportion of patients with Baseline ALT > 30 U/L achieving a reduction from Baseline in ALT ≥ 17 U/L at Week 24 (Cohort A and Cohort B) and Week 48 (Cohort A).

    Time frame: Week 24, Week 48

  11. Change in ELF, (Cohort A and B at Week 24, Cohort A at Week 48)

    Time frame: Week 24 and 48

  12. Change in HbA1c (Cohort A and B at Week 24, Cohort A at Week 48)

    Time frame: Week 24 and 48

  13. Change in HOMA-IR (Cohort A and B at Week 24, Cohort A at Week 48)

    Time frame: Week 24 and 48

  14. Change in plasma glucose (Cohort A and B at Week 24, Cohort A at Week 48)

    Time frame: Week 24 and 48

07

Study locations

77 sites
  • Site #207
    Chandler, Arizona 85224, United States
  • Site #209
    Tucson, Arizona 85712, United States
  • Site #378
    Huntington Park, California 90255, United States
  • Site #439
    Lancaster, California 93534, United States
  • Site #469
    Long Beach, California 90815, United States
  • Site #373
    Los Angeles, California 90056, United States
  • Site #214
    Panorama City, California 91402, United States
  • Site #233
    Santa Ana, California 92704, United States
  • Site #452
    Boca Raton, Florida 33434, United States
  • Site # 101
    Gainesville, Florida 32610, United States
  • Site #465
    Hallandale, Florida 33009, United States
  • Site #430
    Hialeah Gardens, Florida 33016, United States
  • Site #458
    Lakewood Rch, Florida 38018, United States
  • Site #475
    Largo, Florida 33777, United States
  • Site #438
    Miami Lakes, Florida 33016, United States
  • Site #460
    Viera, Florida 32940, United States
  • Site #453
    Houma, Louisiana 70363, United States
  • Site #451
    Marrero, Louisiana 70072, United States
  • Site #061
    Metairie, Louisiana 70006, United States
  • Site #440
    Rockville, Maryland 20854, United States
  • Site #442
    Saint Paul, Minnesota 55114, United States
  • Site #228
    Kansas City, Missouri 64131, United States
  • Site #455
    Jackson, New Jersey 08724, United States
  • Site #445
    East Syracuse, New York 13057, United States
  • Site #454
    New York, New York 10033, United States
  • Site #464
    Morehead City, North Carolina 29557, United States
  • Site #447
    Beavercreek, Ohio 45440, United States
  • Site #470
    Columbus, Ohio 43234, United States
  • Site #448
    Dayton, Ohio 45145, United States
  • Site #437
    Westlake, Ohio 44145, United States
  • Site #461
    Cordova, Tennessee 38018, United States
  • Site # 546
    Arlington, Texas 76012, United States
  • Site #545
    Austin, Texas 78756, United States
  • Site #211
    Austin, Texas 78757, United States
  • Site #432
    Brownsville, Texas 78520, United States
  • Site #370
    Dallas, Texas 75230, United States
  • Site #213
    Edinburg, Texas 78539, United States
  • Site #215
    Edinburg, Texas 78539, United States
  • Site #431
    Georgetown, Texas 78626, United States
  • Site # 066
    Houston, Texas 77030, United States
  • Site #305
    Houston, Texas 77079, United States
  • Site #459
    Katy, Texas 77494, United States
  • Site #433
    San Antonio, Texas 78125, United States
  • Site #212
    San Antonio, Texas 78229, United States
  • Site #434
    Waco, Texas 78125, United States
  • Site #441
    West Jordan, Utah 84088, United States
  • Site #463
    Manassas, Virginia 20110, United States
  • Site #226
    Seattle, Washington 98105, United States
  • Site #506
    Guwahati, Assam 781032, India
  • Site #492
    Ahmedabad, Gujarat 380053, India
  • Site #513
    Rajkot, Gujarat 360001, India
  • Site #490
    Surat, Gujarat 395009, India
  • Site #514
    Surat, Gujarat 395009, India
  • Site #502
    Vadodara, Gujarat 390007, India
  • Site # 494
    Rohtak, Haryana 124001, India
  • Site #511
    Mysore, Karnataka 570015, India
  • Site #507
    Thiruvananthapuram, Kerala 695011, India
  • Site #512
    Mumbai, Maharashtra 400008, India
  • Site #509
    Mumbai, Maharashtra 400062, India
  • Site #500
    Nagpur, Maharashtra 440009, India
  • Site #496
    Pune, Maharashtra 412201, India
  • Site #495
    Ludhiana, Punjab 141002, India
  • Site #489
    Jaipur, Rajasthan 302001, India
  • Site # 485
    Jaipur, Rajasthan 302004, India
  • Site #508
    Madurai, Tamil Nadu 625020, India
  • Site #486
    Hyderabad, Telangana 500003, India
  • Site #549
    Lucknow, Uttar Pradesh 226003, India
  • Site #488
    Varanasi, Uttar Pradesh 221005, India
  • Site #503
    Varanasi, Uttar Pradesh 221005, India
  • Site #504
    Dehradun, Uttarakhand 248001, India
  • Site #487
    Kolkata, West Bengal 700020, India
  • Site #493
    Kolkata, West Bengal 700073, India
  • Site #491
    Kolkata, West Bengal 700150, India
  • Site #482
    New Delhi, 110029, India
  • Site #510
    New Delhi, 110060, India
  • Site #501
    New Delhi, 110070, India
  • Site #457
    San Juan, 00927-4807, Puerto Rico
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Feb 2026, 27 months.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 27 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Sep 2026 → Feb 2026 and completion Sep 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 30, 2023
StartActual
Oct 25, 2023
Primary completionActual
Feb 13, 2026was Sep 2026
CompletionActual
Aug 24, 2026was Sep 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 28, 2026
Primary completion
Sep 2026→Feb 13, 2026 (actual)
Sep 28, 2026
Study completion
Sep 2026→Aug 24, 2026 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Active, not recruiting→Completed
    Primary completion Sep 2026→Feb 13, 2026 (now actual)
    Study completion Sep 2026→Aug 24, 2026 (now actual)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06108219
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Oct 25, 2023
Primary completion
Feb 13, 2026
Completion
Aug 24, 2026
Last update
Sep 29, 2026

Study contacts

Kavita Juneja, MD
study director · Corcept Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion